Has Bassam Mattar, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,910,524 in general payments to Bassam Mattar, MD across 1,127 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bassam Mattar, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bassam Mattar, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bassam Mattar, MD

Hematology & Oncology · Wichita, KSNPI 1053372649

Payments from drug & device makers

$1,910,524in general payments, 2019–2025

Across 1,127 payments — averaging $1695.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Bristol Myers Squibb$1M
Genentech, Inc.$477K
AbbVie$173K
Takeda Pharmaceuticals U.S.A., Inc.$53K
GSK$46K
Gilead$35K
plus $80K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Bristol Myers Squibb	77	$1,045,881
Genentech, Inc.	39	$476,743
AbbVie	54	$173,004
Takeda Pharmaceuticals U.S.A., Inc.	37	$53,385
GSK	58	$46,076
Gilead(2 entities)	58	$35,027
Daiichi Sankyo Inc.	25	$17,470
E.r. Squibb & Sons, L.L.C.	74	$12,742
AstraZeneca(2 entities)	28	$9,793
Janssen Scientific Affairs, LLC	4	$6,052
Rigel Pharmaceuticals, Inc.	16	$5,562
Novartis	92	$4,076
Jazz Pharmaceuticals Inc.	9	$2,267
Beone Medicines USA, Inc.	2	$1,967
Seagen Inc.	21	$1,609
Blueprint Medicines Corporation	2	$1,529
Incyte Corporation	10	$1,337
Janssen Global Services, LLC	1	$1,320
CTI Biopharma Corp.	5	$1,317
Adaptive Biotechnologies Corporation	4	$1,249
Pfizer	94	$1,196
Verity Pharmaceuticals Inc.	2	$1,150
Verastem, Inc.	2	$891
Karyopharm Therapeutics Inc.	7	$880
Eagle Pharmaceuticals, Inc.	1	$850
EMD Serono, Inc.	53	$731
Astellas Pharma US Inc	38	$630
Beigene USA, Inc.	9	$628
Amgen	28	$430
Sanofi	25	$425
Genentech USA, Inc.	27	$412
Merck	19	$313
Exelixis Inc.	15	$301
Array Biopharma Inc	22	$279
Johnson & Johnson(2 entities)	16	$242
AVEO Pharmaceuticals, Inc.	10	$192
Bayer	7	$186
Eisai Inc.	10	$178
Pharmacyclics LLC, An Abbvie Company	10	$153
Servier Pharmaceuticals LLC	9	$126
Mirati Therapeutics, Inc.	6	$110
Springworks Therapeutics, Inc.	5	$108
Sobi, Inc	5	$92
Acrotech Biopharma Inc.	6	$92
Boehringer Ingelheim	5	$89
Stemline Therapeutics Inc.	5	$87
Lilly USA, LLC	5	$86
Ipsen Biopharmaceuticals, Inc	5	$85
Epizyme, Inc.	5	$82
Genmab U.S., Inc.	5	$81
Sun Pharmaceutical Industries Inc.	5	$72
US Oncology Corporate, Inc.	1	$70
Pharmaessentia USA Corporation	4	$68
Spectrum Pharmaceuticals Inc.	4	$64
Syndax Pharmaceuticals, Inc.	3	$51
Recordati_rare_diseases_inc.	3	$50
G1 Therapeutics, Inc.	3	$44
Tersera Therapeutics LLC	2	$42
Apellis Pharmaceuticals, Inc.	2	$40
Iovance Biotherapeutics, Inc.	2	$39

How this compares

$1,910,524 in reported general payments places this provider in the 85th percentile of 97 hematology & oncology providers in Kansas.

See all hematology & oncology providers in Kansas →

Medicare billing

Part B allowed, 2024

$17,313,927

Medicare patients

1,637

Services billed

740,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Wichita

Shaker DakhilWichita$11.2M
Quoc TruongWichita$539K
Christopher DakhilWichita$114K
Phu TruongWichita$73K
Pavan ReddyWichita$69K
Nassim NabboutWichita$29K
Jeremy DeutschWichita$28K
Dennis MooreWichita$26K
Seth PageWichita$19K
Priyanka SharmaWestwood$18.5M

See the full list for Kansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →